Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks

Esmaeilzadeh, Abdolreza; Maleki, Armin Jahani; Moradi, Amirhosein; Siahmansouri, Amir; Yavari, Mohammad Javad; Karami, Parsa; Elahi, Reza

doi:10.1080/14760584.2022.2116008

Cited by 10 publications

(10 citation statements)

References 205 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to emphasize that SARS‐CoV‐2 vaccination has resulted in a substantial reduction in mortality and disease severity among the general population. The occasionally reported adverse events should not undermine the significant benefits associated with vaccination 23 …”

Section: Discussionmentioning

confidence: 99%

Subacute thyroiditis after SARS‐CoV‐2 vaccination: A case report

Akha,

Mazandarani,

Azari

et al. 2024

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessageSubacute thyroiditis which is typically characterized by cervical pain and fever is caused by viral infection and is seen after SARS‐CoV‐2 vaccination. Here we report a post‐vaccination subacute thyroiditis after SARS‐CoV‐2 vaccination.AbstractSubacute thyroiditis (SAT) is possibly caused by a viral infection and is typically characterized by cervical pain and fever. SAT associated with SARS‐CoV‐2 infection or SARS‐CoV‐2 vaccination has been reported, albeit in limited numbers. A 34‐year‐old woman was referred to our clinic with typical SAT symptoms. The diagnosis was confirmed through thyroid scintigraphy after receiving the SARS‐CoV‐2 vaccination, despite testing negative for COVID‐19 via RT‐PCR. There is a theoretical correlation between SARS‐CoV‐2 vaccination and SAT. Vaccination may have a direct or indirect impact on the thyroid, but further studies are required to confirm this relationship. A systematic review of the literature of similar cases was performed for comparison. Ultimately, the overall benefits of SARS‐CoV‐2 vaccination outweigh the potential adverse effects. Therefore, these types of reports should not divert attention from the actual reality.

show abstract

Section: Discussionmentioning

confidence: 99%

Subacute thyroiditis after SARS‐CoV‐2 vaccination: A case report

Akha,

Mazandarani,

Azari

et al. 2024

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…Similarly, hematologic side effects have been reported with viral vector vaccines 13,14 as well, but they were reported more frequently after mRNA vaccination. 6,7,9,10,12,[15][16][17][19][20][21] Coagulation defects risk increased with both mRNA vaccine and viral vector vaccine, with no difference in risk between the two vaccines. While hemolytic anemia has been reported following COVID-19 vaccination, 17,23,26 especially with mRNA vaccines, 17,23,26 our study found that the incidence of hemolytic anemia was low in the COVID-19 vaccine recipient group, regardless of the vaccine type.…”

Section: Discussionmentioning

confidence: 99%

“…2 COVID-19 vaccination is effective in COVID-19 vaccination is effective in preventing severe infection, hospitalization, death, and symptomatic and long COVID-19. 3–5 While, there are various side effects of COVID-19 vaccinations 6,7 including immune-mediated disease. 8–12…”

Section: Introductionmentioning

confidence: 99%

Hematologic abnormalities after COVID-19 vaccination: A large Korean population-based cohort study

Choi,

Kim,

Choi

et al. 2023

Preprint

View full text Add to dashboard Cite

Adverse hematologic events have been reported after COVID-19 vaccination. The objective of this study was to investigate whether hematologic abnormalities develop after COVID-19 vaccination. Retrospective cohort analyses of data from the Korean National Health Insurance Service (KNHIS) database were conducted from July 2022 to August 2023. We randomly selected data of half of those living in Seoul City as of January 1, 2021 with their diagnostic records up to December 31, 2021. The included participants were vaccinated and nonvaccinated persons aged 20 years or older (n= 4,203,887). Hematologic abnormalities after COVID-19 vaccination were identified as nutritional anemia, hemolytic anemia, aplastic anemia, coagulation defects, and neutropenia using International Classification of Diseases, Tenth Revision codes after index date. Incidence rates of hematologic abnormalities in the vaccination group 3 months after vaccination were significantly higher than those in the nonvaccinated group: 14.79 vs. 9.59 (P<.001) for nutritional anemia, 7.83 vs. 5.00 (P<.001) for aplastic anemia, and 4.85 vs. 1.85 (P<.001) for coagulation defects. COVID-19 mRNA vaccine was associated with higher development of nutritional anemia (odds ratio [OR], 1.230 [95% CI, 1.129-1.339], P<.001) and aplastic anemia (OR, 1.242 [95% CI, 1.110-1.390], P<.001) than the viral vector vaccine. The risk of coagulation defects was increased (OR, 1.986 [95% CI, 1.523-2.589], P<.001) after vaccination, and there was no risk difference between mRNA vaccine and viral vector vaccine (OR, 1.075 [95% CI, 0.936-1.233], P=.306). In conclusions, COVID-19 vaccination increased the risk of hematologic abnormalities. When administering the COVID-19 vaccine, careful observation will be necessary after vaccination.

show abstract

“…The WHO announced that most side effects of the Sinopharm COVID-19 vaccine were mild to moderate, including headache, fatigue, and injection site reactions [ 1 ]]. However, in addition to mild adverse reactions, severe adverse reactions to the Sinopharm COVID-19 vaccine (Vero Cell) have been reported [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Guillain–Barré Syndrome due to COVID-19 Vero Cell Vaccination Associated with Concomitant COVID-19 Infection-induced ARDS and Treated Successfully by Therapeutic Plasma Exchange: A First Case Report from Vietnam

et al. 2023

View full text Add to dashboard Cite

Post-vaccination adverse reactions have been reported with varying symptoms and severity owing to research and production time pressures during the coronavirus disease 2019 (COVID-19) pandemic. In this article, we report a rare case of Guillain–Barré syndrome (GBS) in a patient with COVID-19 with acute respiratory distress syndrome (ARDS) after receiving Sinopharm's Vero Cell vaccine (China). The patient who was initially negative for COVID-19 was diagnosed with GBS based on paralysis that developed from the lower extremities to the upper extremities, as confirmed by cytoalbuminologic dissociation in the cerebrospinal fluid. The patient's condition worsened with ARDS caused by COVID-19 infection during the hospital stay, and SpO 2 decreased to 83% while receiving oxygen through a non-rebreather mask (15 l/min) on day 6. The patient was treated with standard therapy for severe COVID-19, invasive mechanical ventilation, and five cycles of therapeutic plasma exchange (TPE) with 5% albumin replacement on day 11 due to severe progression. The patient was weaned off the ventilator on day 28, discharged on day 42, and was completely healthy after 6 months without any neurological sequelae until now. Our report showed the potential of TPE for GBS treatment in critically ill patients with COVID-19 after COVID-19 vaccination.

show abstract

Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks

Cited by 10 publications

References 205 publications

Subacute thyroiditis after SARS‐CoV‐2 vaccination: A case report

Subacute thyroiditis after SARS‐CoV‐2 vaccination: A case report

Hematologic abnormalities after COVID-19 vaccination: A large Korean population-based cohort study

Guillain–Barré Syndrome due to COVID-19 Vero Cell Vaccination Associated with Concomitant COVID-19 Infection-induced ARDS and Treated Successfully by Therapeutic Plasma Exchange: A First Case Report from Vietnam

Contact Info

Product

Resources

About